Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Pediatr Blood Cancer. 2012 Aug 9;60(3):390–395. doi: 10.1002/pbc.24271

Table IV.

Summary of Vorinostat Pharmacokinetic Parameters

Patient Dose
Level
(mg/m2)		 Dose

(mg)		 Half-
life
(hr)		 Tmax

(hr)		 Cmax

(ng/mL)		 AUC0–24h

(ng/mL*hr)		 AUCinf

(ng/mL*hr)		 Cl/F

(L/m2)
# 7 180 175 4.6 6.0 285 2597 2697 65
# 10 230 125 2.9 4.0 465 2402 2406 52
# 11 230 230 5.2 0.5 500 2921 2963 78
# 17 300 500 2.0 4.0 240 1499 1160 431
# 20 300 600 8.7 1.0 148 1401 1651 363

Tmax, time of maximum plasma concentration; Cmax, maximum plasma concentration 30 minutes after drug administration; AUC0–24, area under the plasma concentration-time curve to the 24 hour timepoint; AUC0-inf, area under the plasma concentration-time curve extrapolated to infinity; Cl/F, apparent clearance